Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 4Head & Neck 2Genitourinary 2Breast 2Other solid neoplasm 1Gastrointestinal 1

Conditions

Mesothelioma, Malignant 1Lung Neoplasms 1Esophageal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 6pembrolizumab 5Cisplatin 4sargramostim 3Pemetrexed 3Decitabine 3Celecoxib 3fludarabine 2belinostat 2SS1(dsFv)PE38 2Quality of Life 2Plicamycin 2Nivolumab 2Ipilimumab 2FANG vaccine 2Drug Therapy 2perflutren 1olaparib 1niraparib 1iodixanol 1incomplete Freund's adjuvant 1fludarabine phosphate 1dostarlimab 1anetumab ravtansine 1aldesleukin 1alanosine 1Vorinostat 1Valacyclovir 1UV1 vaccine 1Tumor Burden 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lung Neoplasms × Tetrahydrouridine × Other solid neoplasm × Clear all
NCT03233724 2023-05-31

Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
9 enrolled 14 charts
GastrointestinalOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡